annual meeting program - American Society of Clinical Oncology

Tuesday, June 8, 2010
Brd. 19 Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS)
failing standard of care: Interim analysis of 1,400 patients (pts) in an
expanded access program study. (Abstract #10027)
B. L. Samuels, W. D. Tap, S. Patel, M. von Mehren, J. T. Hamm, P. E. Kaiser,
S. Schuetze, J. Li, E. Bayever, G. D. Demetri
Brd. 20 Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas
(U-LMS): Results of a pooled analysis of five single-agent phase II studies
using the recommended dose. (Abstract #10028)
I. R. Judson, J. Blay, S. P. Chawla, J. A. Radford, A. Le Cesne, J. Verweij,
M. von Mehren, J. Pontes, E. Bayever, G. D. Demetri
Brd. 21 Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated
in clinical trials (CTs) versus expanded access programs (EAPs): A decade
of experience with single-agent trabectedin (Tr). (Abstract #10029)
G. D. Demetri, J. Blay, P. Schoffski, R. G. Maki, A. J. Yovine, I. R. Judson,
P. G. Casali, J. Gomez, E. Bayever, A. Le Cesne
Brd. 22 Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A
retrospective analysis of 39 patients (pts) from three European institutions.
(Abstract #10030)
P. Dileo, R. Sanfilippo, F. Grosso, E. Fumagalli, J. Blay, J. Domont, A. Le Cesne,
J. C. Tercero, P. G. Casali
Brd. 23 Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma
(STS): Phase II studies of the European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).
(Abstract #10031)
P. Schoffski, I. L. Ray-Coquard, A. Cioffi, N. Bin Bui, S. Bauer, J. T. Hartmann,
R. Sciot, J. Wanders, D. Druyts, P. Hohenberger, European Organization for
Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma
Group (STBSG)
Brd. 24 Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST
patients: Results of the prospective BFR14 randomized phase III study
comparing interruption versus continuation of IM at 5 years of treatment—A
French Sarcoma Group study. (Abstract #10032)
I. L. Ray-Coquard, N. Bin Bui, A. Adenis, M. Rios Sr., F. Bertucci, S. Chabaud,
D. Pérol, J. Blay, A. Le Cesne, Groupe Sarcome Francais-Groupe d’Etude des
Tumeurs Osseuses (GSF-GETO)
Brd. 25 Time to onset of progression after imatinib interruption and outcome of
patients with advanced GIST: Results of the BFR14 prospective French
Sarcoma Group randomized phase III trial. (Abstract #10033)
A. Le Cesne, I. Ray-Coquard, N. Bin Bui, A. Adenis, M. Rios Sr., F. Duffaud,
F. Bertucci, S. Chabaud, J. Emile, J. Blay
429
TUESDAY